Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | PKLR | P30613 | 7/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3115891 | 0.91 | DRD2 (0.46) | DRD2DRD4DRD3PKLRMEN1 | |
| SCHEMBL5371500 | 0.85 | DRD2 (0.44) | DRD2PKLRALDH1A1OPRM1OPRD1 | |
| SCHEMBL5368217 | 0.85 | HDAC4 (0.48) | DRD2PKLRALDH1A1OPRM1OPRD1 | |
| SCHEMBL3765940 | 0.80 | STS (0.51) | DRD2DRD4DRD3MEN1KMT2A | |
| SCHEMBL2530864 | 0.77 | DRD2 (0.40) | DRD2PKLRMEN1KMT2AALDH1A1 | |
| SCHEMBL3765943 | 0.77 | DRD2 (0.45) | DRD2DRD4DRD3NOTUM | |
| SCHEMBL15804319 | 0.76 | STS (0.47) | DRD2MEN1KMT2AOPRD1OPRK1 | |
| SCHEMBL3852297 | 0.76 | DRD2 (0.56) | DRD2DRD4DRD3KMT2AALDH1A1 | |
| SCHEMBL5372905 | 0.76 | OPRM1 (0.47) | MEN1KMT2AALDH1A1OPRM1OPRD1 | |
| SCHEMBL5375085 | 0.76 | DRD2 (0.51) | DRD2MEN1KMT2ANOTUMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1768958-B1 | NEW DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF DOPAMINE AND SEROTONIN NEUROTRANSMISSION | NSAB AF NEUROSEARCH SWEDEN AB (DK) | 2009-11-18 | — | — | EP | disclosed |
| EP-1765779-B1 | NEW SUBSTITUTED PIPERIDINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | NSAB AF NEUROSEARCH SWEDEN AB (DK) | 2009-11-18 | — | — | EP | disclosed |
| US-7579474-B2 | Substituted piperidines as modulators of dopamine neurotransmission | NSAB, FILIAL AF NEUROSEARCH AB, SVERIGE (DK) | 2009-08-25 | — | — | US | disclosed |
| US-20070270467-A1 | SUBSTITUTED PIPERIDINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2007-11-22 | — | — | US | disclosed |
| US-20070179185-A1 | NEW DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF DOPAMINE AND SEROTONIN NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2007-08-02 | — | — | US | disclosed |
| EP-1768958-A1 | NEW DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF DOPAMINE AND SEROTONIN NEUROTRANSMISSION | A. CARLSSON RESEARCH AB (SE) | 2007-04-04 | — | — | EP | disclosed |
| EP-1765779-A1 | NEW SUBSTITUTED PIPERIDINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | A. CARLSSON RESEARCH AB (SE) | 2007-03-28 | — | — | EP | disclosed |
| WO-2005121092-A1 | NEW SUBSTITUTED PIPERIDINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | A. CARLSSON RESEARCH AB (SE) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005121088-A1 | NEW DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF DOPAMINE AND SEROTONIN NEUROTRANSMISSION | A. CARLSSON RESEARCH AB (SE) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270467-A1 | SUBSTITUTED PIPERIDINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | DRD2, PRLHR, DRD3 | DRD2 1/4885DRD4 6/4885DRD3 3/4885 |
| US-20070179185-A1 | NEW DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF DOPAMINE AND SEROTONIN NEUROTRANSMISSION | DRD2, DRD4, HTR4 | DRD2 1/4885DRD4 2/4885DRD3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.